• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes

May 12, 2022 By Sean Whooley

Abbott Xience Skypoint
[Image from Abbott]
Abbott (NYSE:ABT) announced today that its Xience Skypoint drug-eluting stent platform is now available globally.

Xience Skypoint has received FDA approval, the CE mark, and PMDA approval in Japan for the broadest expansion with the availability of extended sizes of 4.5 mm and 5 mm offerings.

According to Abbott, Xience Skypoint stents are now the only drug-eluting stents (DES) approved in the U.S. that improve access to care, enabling physicians to deliver advanced technology to patients with larger blood vessels. The expanded sizes are high bleeding risk (HBR)-indicated and represent the only DES with both one-month and three-month dual antiplatelet therapy (DAPT) labeling.

“I’m happy to see the expansion of the Xience Skypoint size matrix to now accommodate large vessels,” Mount Sinai Queens and Mount Sinai Hospital physician Dr. George Dangas said, according to Abbott. “This was a mid-lesion in a left coronary artery of a 48-year-old male patient. The 5.0×28 delivered like a 2.5 would have and I was happy with how it accommodated the vessel tapering, with our ability to follow up post dilatation of 5.5 proximally. Good addition to the Xience family.”

Xience Skypoint received FDA approval and CE marking in July 2021. It is described by Abbott as easier to place while allowing physicians to treat larger blood vessels through improved stent expansion that can open clogged vessels more effectively.

Following FDA approval for one-month DAPT labeling using the Xience family of stents, Abbott CMO and Divisional VP of Global Medical Affairs for its vascular business Dr. Nick West, told Drug Delivery Business News that the latest iteration of the Xience platform offers a level of treatment that’s second to none.

“The Xience drug-eluting stent platform is probably the class-leading, best-in-class drug-eluting stent,” West said. “It has an unrivaled quantity and quality of data behind it. Compared to any other platform — and I’m not just saying this as a promotional thing — we have an unrivaled quantity of data. More than that, we have up to the minute data.”

Filed Under: Auto-injectors, Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Vascular Tagged With: abbott

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS